

CENTENE PHARMACY AND THERAPEUTICS
THERAPEUTIC CLASS MATRIX
GPI Code 42: Nasal Agents, Systemic and Topical
1Q18 January - February

Review Time Frame: November 2016 – October 2017

Background:

Nasal agents administered topically or systemically are commonly used for the symptomatic relief of rhinorrhea and nasal congestion associated with seasonal allergic rhinitis or non-allergic rhinitis (e.g., common cold) or for the treatment or prevention of certain infections in the nose.

New Drugs:

Date of Approval	Drug Name	FDA-Approved Indication(s)	Approval Type	Commercial Availability
09/18/17	Fluticasone propionate (Xhance)	Treatment of nasal polyps in patients 18 years of age or older	<input type="checkbox"/> New entity <input checked="" type="checkbox"/> New formulation <i>(nasal spray, metered dose exhaler)</i> <input type="checkbox"/> New combination <input checked="" type="checkbox"/> New indication <input type="checkbox"/> First time generic <input type="checkbox"/> New brand (existing agent)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
04/28/17	Azelastine HCl and fluticasone propionate nasal spray (Dymista)	Treatment of allergic rhinitis	<input type="checkbox"/> New entity <input type="checkbox"/> New formulation <input type="checkbox"/> New combination <input type="checkbox"/> New indication <input checked="" type="checkbox"/> First time generic <input type="checkbox"/> New brand (existing agent)	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

Discontinued Drugs:

None identified.

FDA Safety Warnings:

None identified.

REVIEW RECOMMENDATION

The following changes are recommended to the clinical guidance for this drug class based on current recommendation in available clinical practice guidelines.

- Add Nasacort to the list of preferred nasal steroids for ages 2 and older. The label was updated on September 19, 2008 with the pediatric extension.

References:

CENTENE PHARMACY AND THERAPEUTICS
THERAPEUTIC CLASS MATRIX
GPI Code 42: Nasal Agents, Systemic and Topical
1Q18 January - February

Review Time Frame: November 2016 – October 2017

1. US Food and Drug Administration. Available at: www.fda.gov. Accessed November 16, 2017.
2. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008 August; 122 (2 Suppl):S1-84.
3. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngology – Head and Neck Surgery. 2015 February. 152(1S): S1-43.